1 line
21 KiB
Text
1 line
21 KiB
Text
|
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:43:48Z","timestamp":1706154228562},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>A registry of consecutive patients who underwent transcatheter intervention for \u2265 moderate PVR after the index TAVI at 22 centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR \u2265 moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to \u2264 mild had lower mortality at 1 year compared with those with AR persisting \u2265 moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad146","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:03:08Z","timestamp":1678233788000},"page":"1331-1339","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-7271-2678","authenticated-orcid":false,"given":"Uri","family":"Landes","sequence":"first","affiliation":[{"name":"Edith Wolfson Medical Center, Cardiology Department, Tel-Aviv University , Holon , Israel"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-9404-3145","authenticated-orcid":false,"given":"Aviram","family":"Hochstadt","sequence":"additional","affiliation":[{"name":"Edith Wolfson Medical Center, Cardiology Department, Tel-Aviv University , Holon , Israel"}]},{"given":"Lisa","family":"Manevich","sequence":"additional","affiliation":[{"name":"Edith Wolfson Medical Center, Cardiology Department, Tel-Aviv University , Holon , Israel"}]},{"given":"John G","family":"Webb","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Innovation Centre for Heart Valve Innovation St Paul\u2019s and Vancouver General Hospital, Vancouver , Canada"}]},{"given":"Janarthanan","family":"Sathananthan","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Innovation Centre for Heart Valve In
|